4D Molecular Therapeutics (FDMT) Projected to Announce Earnings on Tuesday

4D Molecular Therapeutics (NASDAQ:FDMT) is anticipated to release its Q3 2026 resultson Tuesday, November 10th. Analysts expect 4D Molecular Therapeutics to post earnings of ($1.04) per share and revenue of $4.13 million for the quarter. Parties are encouraged to explore the company’s upcoming Q3 2026 earnings results page for the latest details on the call scheduled for Monday, November 9, 2026 at 4:00 PM ET.

4D Molecular Therapeutics (NASDAQ:FDMT) last released its quarterly earnings results on Thursday, August 13th. The company reported ($1.04) earnings per share for the quarter, missing the consensus estimate of ($1.02) by ($0.02). 4D Molecular Therapeutics had a negative return on equity of 41.33% and a negative net margin of 194.74%. The firm had revenue of $3.78 million for the quarter, compared to the consensus estimate of $3.62 million. On average, analysts expect 4D Molecular Therapeutics to post ($4.14) EPS for the current fiscal year and ($4.09) EPS for the next fiscal year.

4D Molecular Therapeutics Trading Up 5.0%

Shares of 4D Molecular Therapeutics stock traded up $0.56 on Tuesday, hitting $11.94. The stock had a trading volume of 241,587 shares, compared to its average volume of 862,804. The stock has a 50 day moving average of $13.63 and a 200 day moving average of $10.88. 4D Molecular Therapeutics has a twelve month low of $6.96 and a twelve month high of $16.93. The company has a debt-to-equity ratio of 0.05, a quick ratio of 8.03 and a current ratio of 8.03. The firm has a market capitalization of $659.34 million, a P/E ratio of -4.55 and a beta of 2.75.

Wall Street Analyst Weigh In

FDMT has been the subject of several analyst reports. Bank of America raised their price target on shares of 4D Molecular Therapeutics from $29.00 to $33.00 and gave the company a “buy” rating in a research note on Tuesday, September 29th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of 4D Molecular Therapeutics in a research note on Thursday, October 15th. HC Wainwright reissued a “buy” rating and issued a $36.00 price target on shares of 4D Molecular Therapeutics in a research note on Thursday, October 22nd. Citigroup restated a “buy” rating on shares of 4D Molecular Therapeutics in a report on Thursday, October 22nd. Finally, Chardan Capital reduced their price objective on shares of 4D Molecular Therapeutics from $26.00 to $25.00 and set a “buy” rating for the company in a research report on Tuesday, October 6th. Ten investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, 4D Molecular Therapeutics presently has a consensus rating of “Moderate Buy” and an average target price of $30.22.

Insider Buying and Selling

In other news, insider David Kirn sold 58,333 shares of the business’s stock in a transaction that occurred on Monday, October 5th. The stock was sold at an average price of $12.92, for a total transaction of $753,662.36. Following the completion of the sale, the insider owned 709,153 shares in the company, valued at $9,162,256.76. The trade was a 7.60% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Insiders sold a total of 123,790 shares of company stock valued at $1,655,545 over the last ninety days. Company insiders own 7.90% of the company’s stock.

4D Molecular Therapeutics Company Profile

4D Molecular Therapeutics, Inc is a clinical-stage biotechnology company focused on developing gene therapies for serious diseases with significant unmet medical needs. The company uses its Therapeutic Vector Evolution platform to design adeno-associated virus (AAV) vectors intended to deliver genetic medicines to specific tissues and organs.

Its pipeline has focused primarily on ophthalmology and pulmonology. Key investigational programs have included 4D-150, an intravitreal gene therapy being developed for retinal diseases such as wet age-related macular degeneration and diabetic macular edema, and 4D-710, an inhaled gene therapy designed to address the underlying cause of cystic fibrosis in patients who cannot benefit from existing CFTR modulator treatments.